WuXi Biologics has announced the expansion of its global Contract Development and Manufacturing Organization (CDMO) network with a new state-of-the-art biologics manufacturing facility in Singapore. The facility will serve as a key hub for the company's Southeast Asian and global operations, strengthening its capabilities in antibody and cell therapy manufacturing.
WuXi Biologics' Singapore expansion reflects the growing importance of Southeast Asia as a biologics manufacturing hub. The move diversifies the company's geographic footprint beyond China amid ongoing geopolitical considerations around biotech supply chains.
WuXi Biologics opens new manufacturing facility in Singapore
Singapore positioned as key APAC biologics manufacturing hub
Geographic diversification strategy amid geopolitical considerations
Singapore emerging as APAC biologics manufacturing hub. WuXi's expansion diversifies China-centric biotech supply chains within APAC region.
Strengthens antibody and cell therapy manufacturing capabilities
Southeast Asia gaining importance in global biotech supply chains
Sign in to save notes on signals.
Sign In